The Prognosis of Acute Myocardial Infarction

Acute Myocardial Infarction Clinical Trial

— AMI-COPS  

Official title:

The Characteristics and Clinical Outcomes of Acute Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02737956
• Other study ID #: 20160317-03
• Status: Completed
• Start date: June 1, 2012
• Est. completion date: December 10, 2023

Study information

• Verified date: March 2024
• Source: Xinjiang Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study aims to establish a registry and surveillance system for acute myocardial infarction (AMI) patients in Xinjiang, focusing on collecting comprehensive information including basic patient demographics, patient characteristics, diagnostic methods, treatment programs, and hospitalization outcomes such as mortality, treatment complications, hospitalization costs, and follow-up events (death, major adverse cardiac events). The goal is to identify and propose effective prevention strategies to reduce the incidence of AMI, optimize the management and outcomes of AMI patients by implementing guideline recommendations in clinical practice, and conduct analyses to develop effective treatment strategies and predictive models for clinical outcomes. This focus on Xinjiang aims to provide a comprehensive understanding of AMI within this specific geographic and demographic context, ultimately contributing to improved prevention, treatment, and management of AMI patients.

Description:

The objective of this study is to establish a comprehensive registry and surveillance system for acute myocardial infarction (AMI) patients in Xinjiang. This platform is designed to support clinical research and translational medicine, aiming to improve the quality of AMI patient care through the integration of guideline recommendations into clinical practice. By collecting detailed information on patient demographics, characteristics, diagnostic methods, treatment programs, and outcomes, including mortality, complications, hospitalization costs, and follow-up events such as death and major adverse cardiac events, this study seeks to lay the foundation for future quality improvement initiatives and research. The ultimate goal is to translate research findings into improved care practices for AMI patients, thereby reducing morbidity and mortality associated with the condition. This endeavor will bridge the gap between clinical research and practical healthcare delivery, ensuring that advancements in the treatment and management of AMI directly benefit patients in Xinjiang, contributing to substantial improvements in healthcare outcomes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7350
• Est. completion date: December 10, 2023
• Est. primary completion date: May 31, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

Acute myocardial infarction patients in hospitalized of the First Affiliated Hospital of Xinjiang Medical University (include diagnosed acute ST-elevation or non ST-elevation myocardial infarction).Diagnosis criteria must meet Universal Definition for AMI (2012).

Exclusion Criteria:

1. Combined with severe valvular heart disease;

2. Combined with severe congenital heart disease;

3. Combined hyperthyroidism, anemia and other high-powered heart disease;

4. With pulmonary heart disease;

5. With hypertrophic obstructive cardiomyopathy;

6. Severe hypotension (SBP <90mmHg or DBP <60mmHg at enrollment);

7. Uncontrolled hypertension (SBP> 160 mmHg before PCI, and / or DBP> 100 mmHg);

8. Liver dysfunction (defined as ALT or total bilirubin is greater than the normal upper limit of 3 times);

9. Renal insufficiency (defined as serum creatinine greater than 1.5 times the normal upper limit);

10. High-risk bleeding patients, such as thrombocytopenia, blood diseases and other diseases;

11. active peptic ulcer and skin ulcers;

12. A patient who is allergic to clopidogrel, tegrellol, or aspirin;

13. Patients with a history of cardiogenic shock within two weeks;

14. pregnant and lactating women, during treatment can not be strict contraception of women of childbearing age;

15. In the past 3 months participated in other clinical researchers;

16. Persons who do not have legal or legal competence;

17. Any condition that the investigator considers unsuitable for participation in the clinical study.

Related Conditions & MeSH terms

• Acute Myocardial Infarction
• Infarction
• Myocardial Infarction

Locations

Country	Name	City	State
China	First Affilliatted Hospital of Xinjiang Medical University	Ürümqi	Xinjiang

Sponsors (1)

Lead Sponsor	Collaborator
Xinjiang Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Death	All-cause mortality, Cardiac mortality	5 years
Secondary	Major adverse cardiovascular events (MACE)	Cardiac death, non-fatal myocardial infarction, and target vessel revascularization.	5 years
Secondary	Major adverse cardiovascular and cerebrovascular events (MACCE)	Cardiac death, non-fatal myocardial infarction, target vessel revascularization and stroke.	5 years
Secondary	stroke	ischemic stroke and hemorrhage	5 years